Demographic and clinical characteristics of study cohorts
| Characteristic . | Total cohort (n = 802) . | CCSRI cohort (n = 497*) . | DLC347 cohort (n = 325*) . | GPH cohort (n = 175) . |
|---|---|---|---|---|
| Treatment | ||||
| R-CHOP/R-CHOP–like | 722 (90) | 435 (88) | 325 (100) | 157 (90) |
| Intensive | 11 (1) | 1 (0) | — | 10 (6) |
| Palliative | 23 (3) | 17 (3) | — | 6 (3) |
| Other | 13 (2) | 13 (3) | — | — |
| Unknown | 29 (4) | 29 (6) | — | — |
| Refused | 4 (0) | 2 (0) | — | 2 (1) |
| Age, y | ||||
| Median (range) | 66 (19-96) | 68 (20-96) | 64 (19-92) | 65 (19-93) |
| ≤60 | 272 (34) | 161 (32) | 133 (41) | 56 (32) |
| >60 | 530 (66) | 336 (68) | 192 (59) | 119 (68) |
| Sex, no. (%) | ||||
| Male | 485 (60) | 288 (58) | 207 (64) | 110 (63) |
| Female | 317 (40) | 209 (42) | 118 (36) | 65 (37) |
| Stage, no. (%) | ||||
| I/II | 181 (24) | 118 (25) | 81 (25) | 38 (22) |
| III/IV | 585 (76) | 345 (75) | 244 (75) | 135 (78) |
| Missing | 36 | 34 | — | 2 |
| LDH, no. (%) | ||||
| Normal | 375 (52) | 217 (52) | 146 (47) | 100 (57) |
| Above the ULN | 342 (48) | 200 (48) | 162 (53) | 75 (43) |
| Missing | 85 | 80 | 17 | — |
| ECOG PS, no. (%) | ||||
| 0-1 | 476 (63) | 290 (64) | 217 (67) | 102 (58) |
| 2-4 | 281 (37) | 162 (36) | 108 (33) | 73 (42) |
| Missing | 45 | 45 | — | — |
| Extranodal sites, no. (%) | ||||
| 0-1 | 655 (82) | 413 (83) | 278 (86) | 134 (77) |
| ≥2 | 147 (18) | 84 (17) | 47 (14) | 41 (23) |
| IPI score, no. (%) | ||||
| Low (0-1) | 230 (31) | 141 (33) | 103 (33) | 51 (29) |
| Intermediate (2-3) | 351 (48) | 209 (48) | 153 (48) | 79 (45) |
| High (4-5) | 152 (21) | 81 (19) | 60 (19) | 45 (26) |
| Missing | 68 | 66 | 9 | — |
| Characteristic . | Total cohort (n = 802) . | CCSRI cohort (n = 497*) . | DLC347 cohort (n = 325*) . | GPH cohort (n = 175) . |
|---|---|---|---|---|
| Treatment | ||||
| R-CHOP/R-CHOP–like | 722 (90) | 435 (88) | 325 (100) | 157 (90) |
| Intensive | 11 (1) | 1 (0) | — | 10 (6) |
| Palliative | 23 (3) | 17 (3) | — | 6 (3) |
| Other | 13 (2) | 13 (3) | — | — |
| Unknown | 29 (4) | 29 (6) | — | — |
| Refused | 4 (0) | 2 (0) | — | 2 (1) |
| Age, y | ||||
| Median (range) | 66 (19-96) | 68 (20-96) | 64 (19-92) | 65 (19-93) |
| ≤60 | 272 (34) | 161 (32) | 133 (41) | 56 (32) |
| >60 | 530 (66) | 336 (68) | 192 (59) | 119 (68) |
| Sex, no. (%) | ||||
| Male | 485 (60) | 288 (58) | 207 (64) | 110 (63) |
| Female | 317 (40) | 209 (42) | 118 (36) | 65 (37) |
| Stage, no. (%) | ||||
| I/II | 181 (24) | 118 (25) | 81 (25) | 38 (22) |
| III/IV | 585 (76) | 345 (75) | 244 (75) | 135 (78) |
| Missing | 36 | 34 | — | 2 |
| LDH, no. (%) | ||||
| Normal | 375 (52) | 217 (52) | 146 (47) | 100 (57) |
| Above the ULN | 342 (48) | 200 (48) | 162 (53) | 75 (43) |
| Missing | 85 | 80 | 17 | — |
| ECOG PS, no. (%) | ||||
| 0-1 | 476 (63) | 290 (64) | 217 (67) | 102 (58) |
| 2-4 | 281 (37) | 162 (36) | 108 (33) | 73 (42) |
| Missing | 45 | 45 | — | — |
| Extranodal sites, no. (%) | ||||
| 0-1 | 655 (82) | 413 (83) | 278 (86) | 134 (77) |
| ≥2 | 147 (18) | 84 (17) | 47 (14) | 41 (23) |
| IPI score, no. (%) | ||||
| Low (0-1) | 230 (31) | 141 (33) | 103 (33) | 51 (29) |
| Intermediate (2-3) | 351 (48) | 209 (48) | 153 (48) | 79 (45) |
| High (4-5) | 152 (21) | 81 (19) | 60 (19) | 45 (26) |
| Missing | 68 | 66 | 9 | — |
ECOG PS, Eastern Cooperate Oncology Group performance status; IPI, International Prognostic Index; LDH, lactate dehydrogenase; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; ULN, upper level of normal.
Overlap between CCSRI and DLC347 cohorts (n = 195).